US President, Joe Biden, has urged Americans not to panic about the new COVID-19 Omicron variant and said the United States was making contingency plans with pharmaceutical companies if new vaccines are needed, Reuters news agency reported on Tuesday.
Biden said the country would not go back to lockdowns to stop the spread of the Omicron variant and that he would lay out his strategy on Thursday for combating the pandemic over the winter.
The president said in remarks at the White House following a meeting with his COVID-19 team: "This variant is a cause for concern, not a cause for panic. We're going to fight and beat this new variant."
He also urged people to get vaccinated, get boosters and wear masks adding that it was inevitable that Omicron cases would emerge in the United States.
While Biden said he believed that existing vaccines would continue to protect against severe disease, he added that his administration was working with vaccine makers Pfizer (NYSE:PFE), Moderna (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) to develop contingency plans.
President Biden also said he would direct the US Food and Drug Administration and the Centres for Disease Control and Prevention (CDC) to make those vaccines available quickly.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT